NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.90 | 0.02 |
| FCF Yield | -76.39% | -6.51% | -48.28% | -4.39% |
| EV / EBITDA | -0.01 | 2.57 | 15.55 | -9.45 |
| Quality | ||||
| ROIC | -183.06% | -3.20% | -10.71% | -41.12% |
| Gross Margin | 0.00% | 100.00% | 2,325.83% | 47.25% |
| Cash Conversion Ratio | 1.06 | 0.35 | 0.44 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -62.93% | – | 43.16% |
| Free Cash Flow Growth | 27.80% | 93.64% | -14.52% | -335.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 5.83 | 61.99 | 1.66 |
| Interest Coverage | 0.00 | -5,018.58 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.34 | 10.87 |
| Cash Conversion Cycle | 0.00 | 149.15 | -1,239.97 | 286.33 |